Scribe Therapeutics to Present on Advances in CRISPR Genome and Epigenome Editing at the 2024 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

StreetInsider04-23

Company will highlight developments enabled by its CRISPR by Design™ approach to engineer novel in vivo genetic medicines, including for ophthalmic diseases ALAMEDA, Calif.--(BUSINESS WIRE)-- Scribe...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2429290604?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-23 04:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2429290604","market":"us","top_or_hot":-1,"title":"Scribe Therapeutics to Present on Advances in CRISPR Genome and Epigenome Editing at the 2024 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting","media":"StreetInsider","content":"<div>\n<p>Company will highlight developments enabled by its CRISPR by Design™ approach to engineer novel in vivo genetic medicines, including for ophthalmic diseases\n\n ALAMEDA, Calif.--(BUSINESS WIRE)--\nScribe...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=23097228\">Source Link</a>\n\n</div>\n","source":"highlight_streetinsider","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Scribe Therapeutics to Present on Advances in CRISPR Genome and Epigenome Editing at the 2024 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nScribe Therapeutics to Present on Advances in CRISPR Genome and Epigenome Editing at the 2024 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-23 04:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=23097228><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Company will highlight developments enabled by its CRISPR by Design™ approach to engineer novel in vivo genetic medicines, including for ophthalmic diseases\n\n ALAMEDA, Calif.--(BUSINESS WIRE)--\nScribe...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=23097228\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4117","symbol_name":"多元化保险","start_time":0,"source_url":"https://www.streetinsider.com/dr/news.php?id=23097228","article_id":"2429290604","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2429290604","pubTimestamp":1713818100,"sourceInfo":{"source_id":"highlight_streetinsider","name":"StreetInsider"},"weMediaInfo":null,"summary":"Company will highlight developments enabled by its CRISPR by Design approach to engineer novel in vivo genetic medicines, including for ophthalmic diseases. Scribe Therapeutics Inc. , a genetic medicines company unlocking the potential of CRISPR to transform human health, today announced its participation in the 27th American Society of Gene & Cell Therapy  Annual Meeting, taking place at the Baltimore Convention Center in Baltimore, MD, and virtually from May 7-11, 2024.Oral presentation title: AAV-Mediated Delivery of a Novel CasX-Editor Molecule Achieves Allele-Specific and Potent Editing of P23H Rhodopsin in a Mouse Model of Retinitis Pigmentosa. Scribe Therapeutics is revolutionizing the development of optimized in vivo CRISPR-based genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases. Our CRISPR by Design approach engineers bacterial immune systems into a premier suite of genome editing tools built for unique molec","collect":0,"end_time":0,"defaultTopTitle":"streetinsider.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4117":"多元化保险","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","BK4556":"基因编辑","BK4585":"ETF&股票定投概念","BK4107":"财产与意外伤害保险","BK4139":"生物科技","BK4588":"碎股","LENZ":"Therapeutics","CRSP":"CRISPR Therapeutics AG","AFG":"美国金融集团有限公司","LU1861558580.USD":"日兴方舟颠覆性创新基金B"},"translate_title":"Scribe Therapeutics将在2024年美国基因和细胞治疗学会（ASGCT）年会上介绍CRISPR基因组和表观基因组编辑的进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AFG":1,"CRSP":1,"LENZ":1},"content_text":"Company will highlight developments enabled by its CRISPR by Design™ approach to engineer novel in vivo genetic medicines, including for ophthalmic diseases\n\n ALAMEDA, Calif.--(BUSINESS WIRE)--\nScribe Therapeutics Inc. (Scribe), a genetic medicines company unlocking the potential of CRISPR to transform human health, today announced its participation in the 27th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking place at the Baltimore Convention Center in Baltimore, MD, and virtually from May 7-11, 2024.\n\nScribe will deliver two oral presentations and one poster presentation showcasing the latest developments in its CRISPR X-Editor (XE) and Epigenetic Long-Term X-Repressors (ELXR) technologies enabled by its CRISPR by Design™ approach. The company’s presentations will include data demonstrating the potent editing activity of XE in non-human primates, the potential for XE to address P23H.RHO-related autosomal dominant retinitis pigmentosa (adRP), and the comprehensive engineering approach to creating highly potent ELXRs.\n\nMore details on each presentation are listed below and the full abstracts are available on the ASGCT meeting website.\n\nOral presentation title: AAV-Mediated Delivery of a Novel CasX-Editor Molecule Achieves Allele-Specific and Potent Editing of P23H Rhodopsin in a Mouse Model of Retinitis Pigmentosa\nAbstract number: 180\nSession title: Ophthalmic and Auditory: Disease Focus\nDate: Thursday, May 9, 2024\nTime: 2:15 - 2:30 p.m. ET\nLocation: Room 318-323\nSpeaker: Cécile Fortuny, Ph.D., Senior Scientist II at Scribe\n\nOral presentation title: Engineering CasX to Create a Gene Editor with Potent Activity in Non-Human Primates\nAbstract number: 155\nSession title: Gene Disruption and Excision\nDate: Thursday, May 9, 2024\nTime: 2:55 - 3:12 p.m. ET\nLocation: Ballroom 3\nSpeaker: Addison Wright, Ph.D., Principal Scientist at Scribe\n\nPoster title: Comprehensive Engineering of a CasX-Based Repressor to Create Highly Potent Epigenetic Editors\nAbstract number: 1670\nSession title: Epigenetic Editing and RNA Editing\nDate: Friday, May 10, 2024\nTime: 12:00 - 7:00 p.m. ET\nLocation: Exhibit Hall\nSpeaker: Jason Fernandes, Ph.D., Principal Scientist at Scribe\n\nAbout Scribe Therapeutics\n\nScribe Therapeutics is revolutionizing the development of optimized in vivo CRISPR-based genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases. Our CRISPR by Design™ approach engineers bacterial immune systems into a premier suite of genome editing tools built for unique molecular advantages in activity, specificity and deliverability that translate into safer and more effective genetic therapies. Co-founded by Nobel Prize winner Jennifer Doudna and backed by leading life sciences investors, Scribe is engineering the future of genetic medicine. To learn more, visit www.scribetx.com.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20240422094947/en/\n\nInvestor Contact:\nStern IR for Scribe Therapeutics\n[email protected]\n\nMedia Contact:\nThermal for Scribe Therapeutics\n[email protected]\n\nSource: Scribe Therapeutics Inc.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2429290604"}